|Study Description:||The goal of this clinical research study is to learn the highest tolerable dose |
and best schedule of the combination of up to 2 cycles of Induction
chemotherapy (daunorubicin, cytarabine, and AC220), up to 3 cycles of
Consolidation chemotherapy (AC220 and high dose cytarabine), and then up to 12
cycles of Maintenance chemotherapy (AC220) that can be given to patients with
AML. The safety of this combination of drugs will also be studied.